NIAID to start Phase 1 trial with Destiny Pharma drug
XF-73, a novel dicationic porphyrin, is under development for the prevention of post-surgical Staphylococcal infections. The Phase 1 trial aims to evaluate the safety, tolerability and preliminary anti-Staphylococcal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.